Slingshot members are tracking this event:

PDUFA date for Regeneron's (REGN) Praluent (alirocumab) (ODYSSEY OUTCOMES study) for Cardiovascular events due April 28, 2019.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
REGN Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Praluent, Alirocumab, Odyssey, Cardiovascular Events